Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels

Vettori, Serena; Cuomo, Giovanna; Iudici, Michele; D'Abrosca, Virginia; Giacco, Veronica; Barra, Giusi; Palma, Raffaele De; Valentini, Gabriele

doi:10.1007/s10875-014-0037-0

Cited by 64 publications

(41 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hasegawa et al previously reported that serum levels of interleukin (IL)-4, IL-10, and IL-13 were elevated in patients with SSc (Hasegawa et al 1997; Hasegawa 1998). In addition, the current study has reported that serum levels of IL-13 were increased in patients with SSc and the increase was positively correlated with the severity of the disease activity (Vettori et al 2014). Other reports have suggested that serum levels of IL-33 were significantly higher in early SSc patients and those cytokines may play a critical role of promoting fibrosis in patients with SSc (O’Reilly 2013; Vettori et al 2014).…”

Section: Introductionmentioning

confidence: 67%

Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity

et al. 2016

View full text Add to dashboard Cite

Increased levels of serum pro-fibrotic cytokines have been reported in patients with systemic sclerosis (SSc). Some of these cytokines also play an important role in the differentiation and migration of eosinophils. The aim of this study was to determine whether eosinophilic inflammation is caused in SSc. We retrospectively reviewed the peripheral blood eosinophil counts in 70 untreated patients with SSc and compared them with those in patients with other major collagen diseases. We additionally evaluated a possible association with disease severity. Eosinophil counts were significantly higher levels in patients with SSc than in those with other collagen diseases, whereas total leukocyte counts were not. Eosinophil counts correlated positively with both severe interstitial lung disease (ILD; r = 0.255, p = 0.033) and modified Rodnan total skin thickness score (m-Rodnan TSS) in SSc (r = 0.347, p = 0.003), but did not correlate with ILD severity in other collagen diseases. In conclusion, peripheral eosinophil counts were higher in patients with SSc than in those with other collagen diseases and were correlated with increased disease severity. Our data suggest that eosinophilic inflammation is involved in the pathogenesis and progression of SSc.

show abstract

Section: Introductionmentioning

confidence: 67%

Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The important role of TGF- β in tissue fibrosis suggests that measurements of its serum levels may reflect the activity of the fibrotic process. However, there have been discordant reports about concentrations of TGF- β in the peripheral blood of patients with SSc [7–12]. …”

Section: Introductionmentioning

confidence: 99%

Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations

Dantas

Gonçalves²,

Almeida³

et al. 2016

Disease Markers

View full text Add to dashboard Cite

Objective. To determine active TGF-β1 (aTGF-β1) levels in serum, skin, and peripheral blood mononuclear cell (PBMC) culture supernatants and to understand their associations with clinical parameters in systemic sclerosis (SSc) patients. Methods. We evaluated serum samples from 56 SSc patients and 24 healthy controls (HC). In 20 SSc patients, we quantified spontaneous or anti-CD3/CD28 stimulated production of aTGF-β1 by PBMC. The aTGF-β1 levels were measured by ELISA. Skin biopsies were obtained from 13 SSc patients and six HC, and TGFB1 expression was analyzed by RT-PCR. Results. TGF-β1 serum levels were significantly higher in SSc patients than in HC (p < 0.0001). Patients with increased TGF-β1 serum levels were more likely to have diffuse subset (p = 0.02), digital ulcers (p = 0.02), lung fibrosis (p < 0.0001), positive antitopoisomerase I (p = 0.03), and higher modified Rodnan score (p = 0.046). Most of our culture supernatant samples had undetectable levels of TGF-β1. No significant difference in TGFB1 expression was observed in the SSc skin compared with HC skin. Conclusion. Raised active TGF-β1 serum levels and their association with clinical manifestations in scleroderma patients suggest that this cytokine could be a marker of fibrotic and vascular involvement in SSc.

show abstract

“…In that context, in the last few years, increasing interest has being devoted to a condition, referred to as early ( or even very early) SSc, which is charactherised by Raynaud"s Phenomenon (RP) associated with either SSc marker autoantibodies or scleroderma-type capillaroscopic alterations or both [4][5][6][7][8][9][10][11][12][13][14][15][16].…”

Section: Autoimmune Rheumatic Diseases (Ards) Such As Rheumatoid Arthmentioning

confidence: 99%

“…A study on the serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay in early SSc as compared to established limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) has been recently published [14]. TGF-β and sVCAM-1 were found to be significantly elevated in patients with lcSSc and dcSSc, but not in those with early SSc, with respect to controls; sICAM-1, CCL2, CXCL8 and IL-13 serum levels resulted to be higher in early SSc patients than in those measured in controls, but lower…”

Section: Therapeutic Perspectivesmentioning

confidence: 99%

Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels

Cited by 64 publications

References 25 publications

Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity

Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity

Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations

Undifferentiated Connective Tissue Disease at risk for systemic sclerosis (SSc) (so far referred to as very early/early SSc or pre-SSc)

Contact Info

Product

Resources

About